National Cancer Institute   US National Institutes of Health |
US National Institutes of Health
Breast Cancer Surveillance Consortium: Working together to advance breast cancer research
Home   |   Data   |   Statistics   |   Tools   |   Collaborations   |   Work with Us   |   Publications   |   About   |   Links

Benchmarks for Sensitivity and Specificity for 2,061,691 Screening Mammography Examinations from 2004 - 2008* -- based on BCSC data through 2009

You are viewing the 2009 collection of this data. Data from other times are also available:
  All Screening Examinations
Sensitivity** 85.6
Readers with 30+ cancers 124
True Positives 5,747
Cancers 6,710
Sensitivity (Median-50th percentile) 85.7
Sensitivity (25th, 75th percentiles) 81, 90
Sensitivity (10th, 90th percentiles) 77.4, 94.7
Specificity§ 90.5
Readers with 1000+ non-cancers 323
True Negatives|| 1,653,760
Non-cancers# 1,828,070
Specificity (Median-50th percentile) 91
Specificity (25th, 75th percentiles) 88, 93.6
Specificity (10th, 90th percentiles) 84.6, 95.6


Numbers are frequencies unless otherwise indicated.

Screening Mammography Examinations: mammography examinations indicated by the radiologist to be for screening, with bilateral routine views done and no other mammogram within the last 9 months, among women without breast implants.

* Includes examinations for radiologists with minimum numbers of cases in a given row as designated; excludes examinations for which the radiologist is unknown.

** Sensitivity = the percentage of cancers that had an abnormal initial interpretation (BI-RADS category 0, 4, 5; Note: 3 with a recommendation for immediate follow-up was recoded as 0).

True Positive = the number of cancers that had an abnormal initial interpretation.

Cancers = the number of examinations with a tissue diagnosis of cancer within 1 year following the examination.

§ Specificity = the percentage of non-cancers that had a negative initial interpretation (BI-RADS category 1, 2, or 3 with no recommendation for immediate follow-up).

|| True Negative = the number of non-cancers that had a negative initial interpretation.

# Non-cancers = the number of examinations without a tissue diagnosis of cancer within 1 year following the examination.

Table numbers last updated Sept 26, 2013 . The following source must be cited when reproducing this table: NCI-funded Breast Cancer Surveillance Consortium (HHSN261201100031C). Downloaded xx/xx/xxxx from the Breast Cancer Surveillance Consortium Web site - .

[Return to Performance Benchmarks for Screening Mammography]

National Cancer Institute Department of Health and Human Services National Institutes of Health The US government's official web portal Maintained by the Healthcare Delivery Research Program,
Division of Cancer Control and Population Sciences